Anaplastic astrocytoma
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the IDH1 or IDH2 genes were significantly associated with improved outcome in patients with anaplastic astrocytomas.
|
19765000 |
2009 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Preliminary data suggest an importance of IDH1 mutation for prognosis showing that patients with anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas harboring IDH1 mutations seem to fare much better than patients without this mutation in their tumors.
|
19554337 |
2009 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To establish the frequency of IDH1 mutations in glioblastomas at a population level, and to assess whether they allow reliable discrimination between primary (de novo) glioblastomas and secondary glioblastomas that progressed from low-grade or anaplastic astrocytoma.
|
19755387 |
2009 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations were frequent in low-grade diffuse astrocytomas (88%) and in secondary glioblastomas that developed through progression from low-grade diffuse or anaplastic astrocytoma (82%).
|
19246647 |
2009 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The sequence from more favorable to poorer outcome was (1) anaplastic astrocytoma with IDH1 mutation, (2) glioblastoma with IDH1 mutation, (3) anaplastic astrocytoma without IDH1 mutation and (4) glioblastoma without IDH1 mutation (p < 0.0001).
|
21088844 |
2010 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1/2 mutations are frequent (>80%) in secondary glioblastomas that have progressed from low-grade or anaplastic astrocytomas.
|
21442241 |
2011 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The lack of expression of GFAP or MAP-2 raised the question of a secondary malignancy, however, molecular genetic analysis of IDH1 and p53 revealed the same mutations in the anaplastic astrocytoma from 2006 as in the sarcomatoid tumor operated in 2010.
|
21955926 |
2011 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the anti-IDH1-R132H-specific monoclonal antibody IMab-1 is very useful for detecting IDH1-R132H in immunohistochemistry, and predicting the time to progression in grade III anaplastic astrocytomas.
|
21344322 |
2011 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, IDH mutation would be most useful when assessing prognosis of patients with grade 3 glioma with intact 1p/19q; anaplastic astrocytomas account for most of these grade 3 gliomas.
|
22136423 |
2012 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To validate mutation frequency, IDH1 gene at codon 132 was sequenced in 74 diffusely infiltrating astrocytomas: diffuse astrocytoma (DA; World Health Organization [WHO] grade II), anaplastic astrocytoma (AA; WHO grade III), and GBM (WHO grade IV).
|
22904127 |
2012 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Seven secondary GBMs were derived from 3 DAs and 4 AAs with wild-type IDH1/2.
|
22790483 |
2012 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our study confirms the utility of IDH1 mutations and MGMT methylation in predicting the prognosis of Group 1 patients (GBM + AA) and demonstrated that IDH1 mutations may serve as a more reliable prognostic factor for such patients.
|
24160898 |
2013 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We evaluated nuclear cMYC protein levels and IDH1 (R132H) by immunohistochemistry in patients with oligodendroglioma/oligoastrocytomas (n = 20), astrocytomas (grade II) (n = 19), anaplastic astrocytomas (n = 21) or glioblastomas (n = 111).
|
23934175 |
2013 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To characterize the contribution of wild-type IDH1 to cancer cell D-2HG production, we established an IDH1-mutated astrocytoma (IMA) cell line from a WHO grade III anaplastic astrocytoma.
|
23204232 |
2013 |
Anaplastic astrocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prevalences of mutations of isocitrate dehydrogenase 1 (IDH1) and histone H3.3 (H3F3A), the glioma cytosine-phosphate-guanine island methylator phenotype (G-CIMP), and methylation of alkylpurine DNA N-glycosylase (APNG) and peroxiredoxin 1 (PRDX1) promoters were determined in a representative biomarker subset (n = 126 patients with anaplastic astrocytoma or glioblastoma) from the NOA-08 trial.
|
23595628 |
2013 |
Anaplastic astrocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we report the generation of an endogenous IDH1 anaplastic astrocytoma model which rapidly grows in vivo, produces 2-HG and exhibits DNA hypermethylation.
|
24077805 |
2013 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Both Grade II gliomas and anaplastic astrocytomas showed a statistically different distribution of IDH1 mutation load compared to GBMs (p < 0.0001; p = 0.0021 respectively).
|
23451940 |
2013 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
|
24748470 |
2014 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic oligoastrocytoma and anaplastic astrocytoma patients with IDH gene mutation showed similar prognosis with anaplastic oligodendroglioma patients with wild-type IDH gene.
|
24149775 |
2014 |
Anaplastic astrocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We sought to determine the impact of surgical resection on survival after controlling for IDH1 status in malignant astrocytomas-World Health Organization grade III anaplastic astrocytomas and grade IV glioblastoma.
|
24305719 |
2014 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IHC detected the IDH1 mutation in 72% (13/18) anaplastic astrocytomas and 30% (3/10) astrocytomas; however, it failed to detect the mutation in 258 thyroid, 11 renal cell, 10 ovarian, 18 endometrial, 20 breast, 25 colorectal, 22 non-small cell lung carcinoma, 25 melanomas, and 8 thyroid follicular adenomas.
|
23235339 |
2014 |
Anaplastic astrocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing.
|
24777756 |
2014 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We show that expression levels of many proteins are altered in IDH1(R132H) mutant anaplastic astrocytoma.
|
24473683 |
2014 |
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The IDH1 mutation status was also determined in patients with anaplastic astrocytomas and AOA, and AOA patients were additionally evaluated for CRM1 nuclear expression.
|
24929863 |
2014 |